Genomes and Genes
Summary: A decrease in the number of neutrophilic leukocytes in the blood. (Dorland, 27th ed)
Publications390 found, 100 shown here
- The role of procalcitonin in febrile neutropenic patients: review of the literatureY Sakr
Department of Anaesthesiology and Intensive Care, Friedrich Schiller University, Erlanger Allee 103, Jena, Germany
Infection 36:396-407. 2008....
- Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guidelineChristopher R Flowers
Emory University School of Medicine, Atlanta, GA, USA
J Clin Oncol 31:794-810. 2013To provide guidelines on antimicrobial prophylaxis for adult neutropenic oncology outpatients and on selection and treatment as outpatients of those with fever and neutropenia.
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursM S Aapro
Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland
Eur J Cancer 47:8-32. 2011Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and also a significant dose-limiting toxicity in cancer treatment...
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropeniaOliver A Cornely
University of Cologne, Cologne, Germany
N Engl J Med 356:348-59. 2007Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.
- Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerA de Gramont
Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
J Clin Oncol 18:2938-47. 2000..This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point...
- Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of americaAlison G Freifeld
Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska
Clin Infect Dis 52:e56-93. 2011This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002...
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsNicole M Kuderer
James P Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, New York 14642, USA
Cancer 106:2258-66. 2006Hospitalization for febrile neutropenia (FN) in cancer patients is associated with considerable morbidity, mortality, and cost...
- A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green
Royal Melbourne Hospital, Melbourne, Australia
Ann Oncol 14:29-35. 2003..We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support...
- 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineThomas J Smith
American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
J Clin Oncol 24:3187-205. 2006..Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness...
- WASP: a key immunological multitaskerAdrian J Thrasher
Molecular Immunology Unit and Centre for Immunodeficiency, University College London Institute of Child Health, London, UK
Nat Rev Immunol 10:182-92. 2010..Intriguingly, gain of function mutations cause a separate disease that is mainly characterized by neutropenia. Here, we describe recent insights into the cellular mechanisms of these two related, but distinct, human ..
- Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignanciesYong Chong
Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8, Taihaku cho Hakata ku, Fukuoka, 812 0033, Japan
Int J Infect Dis 15:e277-81. 2011The routine use of fluoroquinolone prophylaxis in patients with neutropenia and hematological malignancies is controversial...
- Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaMatti Aapro
Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
J Oncol Pharm Pract 18:171-9. 2012..versus Neupogen® or Zarzio® 300 µg may be cost-saving in reducing the incidence of chemotherapy-induced febrile neutropenia; and (b) if cost-wise, treatment with Zarzio® 300 µg yields a savings advantage over Neupogen® 300 µg.
- Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patientsAnat Gafter-Gvili
Rabin Medical Center, Petah Tiqva, Israel
Ann Intern Med 142:979-95. 2005..Trials have shown the efficacy of antibiotic prophylaxis in decreasing the incidence of bacterial infections but not in reducing mortality rates...
- A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantationElio Castagnola
Infectious Diseases Unit, G Gaslini Children Hospital, Genoa, Italy
Clin Infect Dis 45:1296-304. 2007The purpose of our study was to evaluate the incidence and clinical characteristics of febrile episodes during neutropenia following chemotherapy in children with cancer.
- Chemotherapy-induced neutropenia: risks, consequences, and new directions for its managementJeffrey Crawford
Divisions of Oncology and Hematology, Duke University Medical Center, PO Box 25178 Morris Building, Durham, NC 27710 0001, USA
Cancer 100:228-37. 2004..b>Neutropenia, the most serious hematologic toxicity, is associated with the risk of life-threatening infections as well as ..
- Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of AmericaAlison G Freifeld
Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
Clin Infect Dis 52:427-31. 2011This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002...
- A novel X-linked gene, G4.5. is responsible for Barth syndromeS Bione
Institute of Genetics, Biochemistry and Evolution CNR, Pavia, Italy
Nat Genet 12:385-9. 1996..inherited disorder, often fatal in childhood, characterized by cardiac and skeletal myopathy, short stature and neutropenia. The disease has been mapped to a very gene-rich region in distal portion of Xq28...
- Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2Richard E Person
Department of Pathology, University of Washington School of Medicine, Box 357720, Seattle, Washington 98195, USA
Nat Genet 34:308-12. 2003..We therefore screened GFI1 as a candidate for association with neutropenia in affected individuals without mutations in ELA2 (encoding neutrophil elastase), the most common cause of ..
- Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerF A Holmes
Texas Oncology, PA, Dallas, TX
J Clin Oncol 20:727-31. 2002..injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 microg/kg) is as safe and effective as daily filgrastim (5 microg/kg/d) for reducing neutropenia in patients who received four cycles of myelosuppressive chemotherapy.
- Mucosal damage and neutropenia are required for Candida albicans disseminationAndrew Y Koh
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Pathog 4:e35. 2008..albicans dissemination from the GI tract, but we have hypothesized that both neutropenia and GI mucosal damage are critical for allowing widespread invasive C. albicans disease...
- Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemiaRenee Beekman
Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
Blood 119:5071-7. 2012Severe congenital neutropenia (SCN) is a BM failure syndrome with a high risk of progression to acute myeloid leukemia (AML). The underlying genetic changes involved in SCN evolution to AML are largely unknown...
- Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United StatesHilmar Wisplinghoff
Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, 50935 Cologne, Germany
Clin Infect Dis 36:1103-10. 2003..001), and gram-negative organisms accounted for 22% and 14% of all BSIs for these years, respectively. Neutropenia was observed in 30% of patients, so neutropenic and nonneutropenic patients were compared...
- A hypomorphic mutation in the Gfi1 transcriptional repressor results in a novel form of neutropeniaDiana Ordoñez-Rueda
Centre d immunologie de Marseille Luminy, Aix Marseille Universite, UM2, Marseille, France
Eur J Immunol 42:2395-408. 2012Using N-ethyl-N-nitrosourea-induced mutagenesis, we established a mouse model with a novel form of neutropenia resulting from a point mutation in the transcriptional repressor Growth Factor Independence 1 (Gfi1)...
- Oscillations in cyclical neutropenia: new evidence based on mathematical modelingSamuel Bernard
Département de mathématiques et de statistique and Centre de recherches mathématiques, Universite de Montreal, C P 6128, Succ Centre Ville, Montreal, Que, Canada H3C 3J7
J Theor Biol 223:283-98. 2003..We make the estimation of kinetic parameters for dogs and then apply the model to cyclical neutropenia (CN) in the grey collie, a rare disorder in which oscillations in all blood cell counts are found...
- Neutropenia enhances lung dendritic cell recruitment in response to Aspergillus via a cytokine-to-chemokine amplification loopStacy J Park
Department of Microbiology, University of Virginia, Charlottesville, VA 22908, USA
J Immunol 185:6190-7. 2010..neutrophils can modulate immune responses independent of their direct microbial killing, we hypothesized that neutropenia impacts the host response to Aspergillus by determining the migration and phenotype of lung DCs...
- Mpn1, mutated in poikiloderma with neutropenia protein 1, is a conserved 3'-to-5' RNA exonuclease processing U6 small nuclear RNAVadim Shchepachev
Institute of Biochemistry, Eidgenossische Technische Hochschule Zurich, Zurich, CH 8093, Switzerland
Cell Rep 2:855-65. 2012Clericuzio-type poikiloderma with neutropenia (PN) is a rare genodermatosis associated with mutations in the C16orf57 gene, which codes for the uncharacterized protein hMpn1...
- Levofloxacin to prevent bacterial infection in patients with cancer and neutropeniaGiampaolo Bucaneve
Policlinico Monteluce, Perugia, Italy
N Engl J Med 353:977-87. 2005The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention.
- Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-betaYuk Yin Cheung
Section on Cellular Differentiation, Heritable Disorders Branch, National Institute of Child Health and Human Development NICHD, NIH, Bethesda, Maryland 20892, USA
J Clin Invest 117:784-93. 2007b>Neutropenia and neutrophil dysfunction are common in many diseases, although their etiology is often unclear...
- Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropeniaPhilip S Rosenberg
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
Br J Haematol 140:210-3. 2008Severe congenital neutropenia (SCN) is a heterogeneous bone marrow failure syndrome predisposing to myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML)...
- Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropeniaJun Xia
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Br J Haematol 147:535-42. 2009Severe congenital neutropenia (SCN) is a genetically heterogeneous syndrome associated with mutations of ELANE (ELA2), HAX1, GFI1, WAS, CSF3R or G6PC3...
- Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropeniaCornelia Zeidler
Department of Paediatric Haematology Oncology, Medical University Hannover, Hannover, Germany
Br J Haematol 144:459-67. 2009Congenital Neutropenia (CN) is a heterogeneous bone marrow failure syndrome characterized by a maturation arrest of myelopoiesis at the level of the promyelocyte/myelocyte stage with peripheral blood absolute neutrophil counts below 0...
- Periodontal disease in patients from the original Kostmann family with severe congenital neutropeniaGoran Carlsson
Childhood Cancer Research Unit, Department of Women s and Children s Health, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
J Periodontol 77:744-51. 2006Patients with Kostmann syndrome (severe congenital neutropenia [SCN]) typically normalize their absolute neutrophil count (ANC) upon granulocyte colony-stimulating factor (G-CSF) therapy...
- Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent feverThomas J Walsh
National Cancer Institute, Bethesda, MD 20892, USA
N Engl J Med 346:225-34. 2002Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative.
- Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantationM Dettenkofer
Institute of Environmental Medicine and Hospital Epidemiology, University Hospital of Freiburg, Germany
Bone Marrow Transplant 31:795-801. 2003..The mean length of neutropenia was 14.3 days (range: 0-66)...
- Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency diseasePaolo A Hernandez
Department of Human Genetics, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, New York 10029, USA
Nat Genet 34:70-4. 2003WHIM syndrome is an immunodeficiency disease characterized by neutropenia, hypogammaglobulinemia and extensive human papillomavirus (HPV) infection...
- X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an updatePeter G Barth
Department of Pediatric Neurology, Emma Children s Hospital AMC, University of Amsterdam, Amsterdam, The Netherlands
Am J Med Genet A 126:349-54. 2004X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM302060, BTHS) is a disorder with mitochondrial functional impairments and 3-methylglutaconic aciduria that maps to Xq28. The associated G4...
- Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantationJo Anne H van Burik
University of Minnesota, Minneapolis, MN, USA
Clin Infect Dis 39:1407-16. 2004..chemoprophylaxis with the echinocandin micafungin would be an effective agent for antifungal prophylaxis during neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT)...
- Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndromeP Vreken
Department of Clinical Chemistry, Academic Medical Center, Amsterdam, 1100 DE, The Netherlands
Biochem Biophys Res Commun 279:378-82. 2000..In this paper we present evidence that patients with the rare disorder X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060) have a primary defect in CL and PG remodeling...
- Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancerF A Holmes
US Oncology Research, Houston, TX 77024 2305, USA
Ann Oncol 13:903-9. 2002b>Neutropenia is common in patients receiving myelotoxic chemotherapy. Pegfilgrastim, a sustained-duration filgrastim is a once-per-cycle therapy for prophylactic neutrophil support.
- Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyNasser Hanna
Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
J Clin Oncol 22:1589-97. 2004..To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy...
- Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infectionsMarit D Moen
Wolters Kluwer Health Adis, Auckland, New Zealand
Drugs 69:361-92. 2009..and amphotericin B lipid complex as empirical therapy in adult and paediatric patients with febrile neutropenia. In addition, caspofungin was noninferior to liposomal amphotericin B as empirical therapy in adult patients ..
- The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsJ Klastersky
Institut Jules Bordet, Brussels, Belgium
J Clin Oncol 18:3038-51. 2000Febrile neutropenia remains a potentially life-threatening complication of anticancer chemotherapy, but some patients are at low risk for serious medical complications...
- Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International RegistryDavid C Dale
Department of Medicine, Box 356422, University of Washington, Seattle, WA 98195, USA
Am J Hematol 72:82-93. 2003Severe chronic neutropenia (SCN) is defined as an absolute neutrophil (ANC) of less than 0.5 x 10(9)/L, lasting for months or years. Congenital, cyclic, and idiopathic neutropenia are principal categories of SCN...
- The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapyPhilip S Rosenberg
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852 7244, USA
Blood 107:4628-35. 2006In patients with severe congenital neutropenia (SCN), sepsis mortality is reduced by treatment with granulocyte colony-stimulating factor (G-CSF), but myelodsyplastic syndrome and acute myeloid leukemia (MDS/AML) have been reported...
- Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsFederico Innocenti
The University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 27:2604-14. 2009We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in irinotecan (CPT-11) pharmacokinetics and neutropenia in cancer patients.
- HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)Christoph Klein
Department of Pediatric Hematology Oncology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
Nat Genet 39:86-92. 2007Autosomal recessive severe congenital neutropenia (SCN) constitutes a primary immunodeficiency syndrome associated with increased apoptosis in myeloid cells, yet the underlying genetic defect remains unknown...
- The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unitM Craig
Department of Medicine, Mary Babb Randolph Cancer Center, West Virginia University Hospitals, Morgantown, WV 26506 9162, USA
Bone Marrow Transplant 39:477-82. 2007Febrile neutropenia is an expected complication during treatment of aggressive hematological malignancies and hematopoietic cell transplantation...
- Biosimilar medicines in oncology: single-center experience with biosimilar G-CSFNello Salesi
Combined Department of Medical Oncology, Gaeta Hospital M Di Liegro, Lazio Local Health Authority, Gaeta, Italy
Future Oncol 8:625-30. 2012..Recombinant granulocyte colony-stimulating growth factors (G-CSF) are used for the prophylaxis of febrile neutropenia.
- Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysisMical Paul
Rabin Medical Centre, Beilinson Campus, Infectious Diseases Unit and Department of Medicine E, Petah Tiqva 49100, Israel
BMJ 326:1111. 2003To compare the effectiveness of beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy in the treatment of patients with fever and neutropenia.
- Risks and consequences of chemotherapy-induced neutropeniaGary H Lyman
University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Clin Cornerstone 8:S12-8. 2006b>Neutropenia represents a major dose-limiting toxicity of chemotherapy and is associated with an increased risk of infection, impaired patient quality of life, and interference with the delivery of full-dose chemotherapy...
- Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infantsCornelia Feiterna-Sperling
Charite, Department of Pediatric Pneumology and Immunology, University Medicine Berlin, Berlin, Germany
J Acquir Immune Defic Syndr 45:43-51. 2007..A prospective observational study to investigate hematologic alterations during the first 3 months of life in HIV-exposed uninfected infants subjected to antiretroviral medication before and after birth...
- XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapyUlrich Gatzemeier
Center of Pneumology and Thoracic Surgery, Department of Thoracic Surgery, Grosshansdorf, Germany
J Thorac Oncol 4:736-40. 2009Recombinant granulocyte colony-stimulating factors such as Neupogen are used to treat chemotherapy-induced neutropenia. The aim of the study was to show that a new granulocyte colony-stimulating factor, XM02, is as safe and effective as ..
- Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancyS Hashino
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita ku, Sapporo 060 8638, Japan
Eur J Clin Microbiol Infect Dis 31:173-8. 2012..To suppress the appearance of multi-drug-resistant bacteria and to avoid severe infection derived from febrile neutropenia (FN), we conducted cycling the administration of antibiotics for FN in patients with hematological malignancy...
- Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphomaAndreas Engert
Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany
Onkologie 32:599-604. 2009..G-CSF) biosimilar, XM02, with filgrastim in terms of its prophylactic effect on the development of febrile neutropenia (FN) during the first chemotherapy cycle in relation to the myelotoxic potency of the applied chemotherapy ..
- Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia StudyMatthias Schwenkglenks
European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
Support Care Cancer 19:483-90. 2011Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections...
- Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective studyHiangkiat Tan
HealthCore, Inc, 800 Delaware Ave, 5th Floor, Wilmington, DE 19801, USA
Curr Med Res Opin 27:79-86. 2011Granulocyte colony stimulating factors (G-CSFs) decrease the incidence of febrile neutropenia (FN) in cancer patients receiving myelosuppressive chemotherapy...
- Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamidePaola Papaldo
Division of Medical Oncology, Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
J Clin Oncol 23:6908-18. 2005..schedules of recombinant human granulocyte colony-stimulating factor (G-CSF; filgrastim) support in preventing febrile neutropenia in early breast cancer patients treated with relatively high-dose epirubicin plus cyclophosphamide (EC).
- Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropeniaD Caillot
Department of Clinical Hematology, University Hospital of Dijon, Dijon, France
J Clin Oncol 19:253-9. 2001In patients with neutropenia, thoracic computed tomography (CT) halo and air-crescent signs are recognized as major indicators of invasive pulmonary aspergillosis (IPA). Nevertheless, the exact timing of CT images is not well known.
- Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsPeter Renner
Medizinische Klinik 5 Schwerpunkt Onkologie Haematologie, Klinikum Nord, Nuernberg, Germany
Cochrane Database Syst Rev 10:CD007913. 2012High-dose or dose-intensive cytotoxic chemotherapy often causes myelosuppression and severe neutropenia among cancer patients...
- Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancerMichael E Stokes
United BioSource Corporation, 185 Dorval Ave, Ste 500, Dorval, QC, H9S 5J9, Canada
J Manag Care Pharm 15:669-82. 2009b>Neutropenia is a major adverse event often associated with chemotherapy administration. Neutropenia-related complications often lead to increased use of costly health care including inpatient and outpatient services...
- Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized studyDaniel Hendler
Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
Am J Clin Oncol 34:619-24. 2011..nonrandomized study evaluates 4 schedules of granulocyte colony-stimulating factor (G-CSF) for patients with breast cancer receiving adjuvant dose-dense chemotherapy regarding febrile neutropenia, treatment delays, and costs.
- Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trialCatherine Cordonnier
Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique Hôpitaux de Paris AP HP and Paris 12 University, Creteil, France
Clin Infect Dis 48:1042-51. 2009..Recent diagnostic improvements may ensure the early diagnosis of potentially invasive fungal disease. Reserving antifungals for this stage may achieve similar survival rates and reduce treatment toxicity and costs...
- Primary and secondary autoimmune neutropeniaFranco Capsoni
Rheumatology Unit, Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy
Arthritis Res Ther 7:208-14. 2005Antineutrophil antibodies are well recognized causes of neutropenia, producing both quantitative and qualitative defects in neutrophils and increased risk for infection...
- Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?Jean Klastersky
N Engl J Med 351:1445-7. 2004
- Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancerWylie Hosmer
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Support Care Cancer 19:333-41. 2011Current guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSF) when febrile neutropenia (FN) risk is greater than 20%...
- C16orf57, a gene mutated in poikiloderma with neutropenia, encodes a putative phosphodiesterase responsible for the U6 snRNA 3' end modificationSeweryn Mroczek
Department of Biophysics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02 106 Warsaw, Poland
Genes Dev 26:1911-25. 2012C16orf57 encodes a human protein of unknown function, and mutations in the gene occur in poikiloderma with neutropenia (PN), which is a rare, autosomal recessive disease...
- A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancerCornelius F Waller
Abt Innere Medizin I, Medizinische Universitatsklinik, Freiburg, Germany
Onkologie 33:504-11. 2010Filgrastim was developed to treat chemotherapy-induced neutropenia. This phase III study was designed to demonstrate bioequivalence of Amgen filgrastim and a biosimilar filgrastim developed by Hospira (Study GCF071; sponsored by Hospira).
- Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim useHoward Ozer
Section of Hematology Oncology, University of Oklahoma Health Science Center, PO Box 26901, Williams Pavilion, Room WP2080, Oklahoma City, Oklahoma 73190, USA
Oncologist 12:484-94. 2007..We conducted this large, prospective, noncomparative study to assess neutropenia and related complications in patients receiving myelotoxic chemotherapy with pegfilgrastim support in community ..
- Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patientsLuregn J Schlapbach
Department of Pediatrics, University of Bern, Bern, Switzerland
Pediatr Infect Dis J 26:989-94. 2007..The aim of the present study was to determine whether children with cancer and MASP-2 deficiency develop more frequent or more severe episodes of fever and severe chemotherapy-induced neutropenia (FN).
- Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantationShigeo Fuji
Department of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
Transplantation 84:814-20. 2007..Van den Berghe et al. showed that the strict glucose control improved the outcome of patients treated in the intensive care unit, and this point was evaluated in this study in a HSCT setting...
- XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapyA Engert
Department of Internal Medicine, University Clinic of Cologne, Germany
Leuk Lymphoma 50:374-9. 2009..factors (G-CSFs) such as filgrastim or lenograstim are being used to treat chemotherapy-induced neutropenia. The aim of the present study was to investigate a new G-CSF, XM02, in comparison to filgrastim in terms of ..
- Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patientsVincas Urbonas
National Research Institute, Center for Innovative Medicine, Department of Immunology, Moletu pl 29, LT 08409 Vilnius, Lithuania
Cytokine 57:313-5. 2012Early diagnosis of bacteremia and sepsis in pediatric oncology patients with febrile neutropenia still remains unresolved task due to lack of sensitive and specific laboratory markers particularly at the beginning of the infectious ..
- Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropeniaAkiko Nakamura
Central Clinical Laboratories, Mie University Hospital, Mie, Japan
J Clin Microbiol 48:2030-6. 2010..In subsequent sporadic PCR analyses in 15 cases of febrile neutropenia, bacteria were detected by both PCR and blood culture in 7 cases and by PCR alone in 6. Fungi were not detected...
- Neutrophil dynamics in response to chemotherapy and G-CSFChangjing Zhuge
Zhou Pei Yuan Center for Applied Mathematics, Tsinghua University, Beijing 100084, China
J Theor Biol 293:111-20. 2012..cells and the differentiated neutrophil progeny to examine the effects of periodic chemotherapy in generating neutropenia, and the corresponding response of this system to granulocyte colony stimulating factor given to counteract the ..
- A mathematical model of hematopoiesis: II. Cyclical neutropeniaCaroline Colijn
Department of Mathematics and Centre for Nonlinear Dynamics, McGill University, 3655 Promenade Sir William Osler, Montreal, QC, Canada H3G 1Y6
J Theor Biol 237:133-46. 2005Cyclical neutropenia is a dynamical disease of the hematopoietic system marked by an oscillation in circulating leukocyte (e.g. neutrophil) numbers to near zero levels and then back to normal...
- Cost of neutropenic complications of chemotherapyD Weycker
Policy Analysis Inc, Brookline, MA 02445, USA
Ann Oncol 19:454-60. 2008..Cost of neutropenic complications of myelosuppressive chemotherapy has been reported to be substantial. Prior research, however, has focused on initial hospitalization only and has failed to account for follow-on care...
- Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexisDavid H McDermott
Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Blood 116:2793-802. 2010Mutations in more than 15 genes are now known to cause severe congenital neutropenia (SCN); however, the pathologic mechanisms of most genetic defects are not fully defined...
- Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in JapanS Naito
Department of Urology, Faculty of Medicine, Kyushu University 71, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8585, Japan
Jpn J Clin Oncol 38:365-72. 2008..This study was undertaken to assess the feasibility of docetaxel in combination with prednisolone in Japanese patients with HRPC...
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancerR Bruno
Drug Metabolism and Pharmacokinetics Department, , Antony, France
J Clin Oncol 16:187-96. 1998..time to progression (TTP) in breast cancer and non-small-cell lung cancer (NSCLC), and for toxicity, grade 4 neutropenia, and febrile neutropenia at first course and time to onset of fluid retention...
- Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesisAthanasia D Panopoulos
Department of Immunology and Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, PO Box 301402, Unit 902, Houston, TX 77030, USA
Cytokine 42:277-88. 2008..Understanding the molecular control of granulopoiesis will aid in the development of new approaches designed to treat disorders of neutrophil production and function...
- Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipientsA L Oliveira
Hospital Universitario, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Bone Marrow Transplant 39:775-81. 2007..47, 95% CI 2.60-34.40) were associated with infection due to MDR Gram-negative isolates. These findings may have important clinical implications in the decision of giving prophylaxis and selecting the empiric antibiotic regimen...
- Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002Winfried V Kern
Center for Infectious Diseases and Travel Medicine, Department of Medicine, Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Hugstetter Strasse 55, D 79106 Freiburg, Germany
J Antimicrob Chemother 55:57-60. 2005..To compare rates of in vitro fluoroquinolone resistance of bacterial isolates obtained from inpatients of two haematology-oncology services with high and low fluoroquinolone consumption...
- Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-riskMiriam Diepold
Department of Pediatric Oncology and Hematology, University Hospital of Bern, 3010 Bern, Switzerland
BMC Infect Dis 8:28. 2008Patients with chemotherapy-related neutropenia and fever are usually hospitalized and treated on empirical intravenous broad-spectrum antibiotic regimens...
- Mutations in C16orf57 and normal-length telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndromeAmanda J Walne
Centre for Paediatrics, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Barts and The London Children s Hospital, 4 Newark Street, London, UK
Hum Mol Genet 19:4453-61. 2010..This region included the C16orf57 gene recently identified to be mutated in poikiloderma with neutropenia (PN), an inherited poikiloderma displaying significant clinical overlap with DC...
- Etiology and clinical course of febrile neutropenia in children with cancerHana Hakim
Departments of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
J Pediatr Hematol Oncol 31:623-9. 2009The etiology, clinical course, and outcome of fever and neutropenia (FN) in children with cancer using the current FN guidelines and diagnostic resources in the United States have not been well described.
- Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the AmericasCynthia Firnhaber
Department of Medicine Clinical HIV Research Unit, University of Witwatersrand, Postnet suite 176, Private Bag X2600, Johannesburg 2041, South Africa
Int J Infect Dis 14:e1088-92. 2010..individuals live in resource-constrained countries, there is little information about the frequency of hematological abnormalities such as anemia, neutropenia, and thrombocytopenia among individuals with advanced HIV-1 disease.
- 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancerWalter T Hughes
St Jude Children s Research Hospital, Memphis, TN, 38105, USA
Clin Infect Dis 34:730-51. 2002
- Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesisM Horwitz
Division of Medical Genetics, University of Washington School of Medicine, Seattle, Washington, USA
Nat Genet 23:433-6. 1999Human cyclic haematopoiesis (cyclic neutropenia, MIM 162800) is an autosomal dominant disease in which blood-cell production from the bone marrow oscillates with 21-day periodicity...
- Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN studyRoland A Ammann
Pediatric Hematology Oncology, University of Bern, Inselspital, CH 3010 Bern, Switzerland
J Clin Oncol 28:2008-14. 2010..a score predicting the risk of adverse events (AEs) in pediatric patients with cancer who experience fever and neutropenia (FN) and to evaluate its performance...
- Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106)Francesco Giuliani
Department of Medical Oncology, Oncology Institute, Bari, Italy
Am J Clin Oncol 28:581-5. 2005..The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma...
- Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic reviewNicole M Kuderer
University of Rochester School of Medicine and Dentistry, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
J Clin Oncol 25:3158-67. 2007..granulocyte colony-stimulating factors (G-CSF) have demonstrated a significant reduction in febrile neutropenia (FN) after systemic chemotherapy...
- Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia RegisterChristine Bellanne-Chantelot
Hopital Saint Antoine, Laboratoire de d Embryologie Pathologique et de Cytogénétique, 184 rue du Fbg Saint Antoine, 75012 Paris, France
Blood 103:4119-25. 2004Heterozygous mutations of the gene encoding neutrophil elastase (ELA2) have been associated with cyclic neutropenia (CN) and severe congenital neutropenia (SCN)...
- Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre studyH Giamarellou
4th Department of Internal Medicine, Athens Medical School, Athens, Greece
Clin Microbiol Infect 10:628-33. 2004In order to assess the diagnostic value of procalcitonin, 158 patients with febrile neutropenia from centres across Europe were studied...
- Low plasma levels of the protein pro-LL-37 as an early indication of severe disease in patients with chronic neutropeniaJenny Karlsson
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Br J Haematol 137:166-9. 2007Chronic neutropenia comprises several different diseases that vary in degree of severity and management...
- Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosisDavid S Grenda
Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
Blood 110:4179-87. 2007Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis...
- Clinical and pharmacogenetic factors associated with irinotecan toxicityDinemarie Kweekel
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
Cancer Treat Rev 34:656-69. 2008..Its use may lead to severe toxicities, predominantly neutropenia and diarrhea which can be life-threatening...
- Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapyPhilip S Rosenberg
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
Br J Haematol 150:196-9. 2010In severe congenital neutropenia (SCN), long-term therapy with granulocyte colony-stimulating factor (G-CSF) has reduced mortality from sepsis, revealing an underlying predisposition to myelodysplastic syndrome and acute myeloid ..
- Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseasesBrice Korkmaz
INSERM U 618 Protéases et Vectorisation Pulmonaires, Universite Francois Rabelais, Faculte de Medecine, 10 boulevard Tonnelle, Tours, France
Pharmacol Rev 62:726-59. 2010..Mutations in the ELA2/ELANE gene, encoding neutrophil elastase, are the cause of human congenital neutropenia. Neutrophil membrane-bound proteinase 3 serves as an autoantigen in Wegener granulomatosis, a systemic ..
- Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study GroupJean Donadieu
Service d hémato oncologie pédiatrique, Hopital Trousseau, Paris, France
Haematologica 90:45-53. 2005The two main complications of severe chronic neutropenia are fatal sepsis and myelodysplasia/acute leukemia (MDS/AL)...
- Aspergillosis case-fatality rate: systematic review of the literatureS J Lin
Department of Pharmacy Administration, University of Illinois at Chicago, Chicago, IL, USA
Clin Infect Dis 32:358-66. 2001..Mortality is high despite improvements in diagnosis and despite the advent of newer formulations of amphotericin B. Underlying patient conditions and the site of infection remain important prognostic factors...
- Congenital neutropenia: diagnosis, molecular bases and patient managementJean Donadieu
Service d Hémato Oncologie Pédiatrique Registre des neutropénies congénitales, AP HP Hopital Trousseau, 26 avenue du Dr Netter, Paris, France
Orphanet J Rare Dis 6:26. 2011The term congenital neutropenia encompasses a family of neutropenic disorders, both permanent and intermittent, severe (<0.5 G/l) or mild (between 0.5-1...
- PRE- AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYJ Evan Sadler; Fiscal Year: 2013..viruses;epithelial morphogenesis;pathogenesis of leukemia, MDS, myeloproliferative neoplasms, and congenital neutropenia;cell cycle control;programmed cell death in development and malignancy...
- Long-Acting G-CSF Analog for Treating ARSGEORGE NORBERT COX; Fiscal Year: 2013..Recombinant human G-CSF is widely used to treat chemotherapy-related neutropenia in cancer patients, and recent studies indicate that it improves overall survival in animal models of ARS, ..
- GM-CSF analogs for treating acute radiation syndromeGEORGE NORBERT COX; Fiscal Year: 2010..Recombinant human GM-CSF is used to treat chemotherapy- induced neutropenia in cancer patients and accelerate bone marrow recovery following transplantation...
- Disease-related defects in dendritic cell processing of bacterial antigensMichael S Marks; Fiscal Year: 2012..patients, who lack the endosomal protein sorting complex AP-3, additionally suffer from immunodeficiency and neutropenia. HPS7 and HPS8 patients lack a different complex, BLOC-1, that mediates different transport steps in other LRO- ..
- Manipulation of Host Angiogenesis as a Therapeutic Strategy against Invasive PulmDimitrios P Kontoyiannis; Fiscal Year: 2010..To that end, we will use two murine models of IA following induction of neutropenia with cyclophosphamide: (1) An acute pulmonary model, in which infection is established by intranasal ..
- Long-Acting G-CSF analogs for treating acute radiation syndromeGEORGE NORBERT COX; Fiscal Year: 2010..Recombinant human G-CSF is widely used to treat chemotherapy-related neutropenia in cancer patients, and recent studies indicate that it improves overall survival in animal models of ARS...
- Disease-Modifying Effects of Filgastrim in a Mouse Model of ADJuan R Sanchez-Ramos; Fiscal Year: 2012..Clinical relevance: G-CSF is routinely and safely used to treat neutropenia and to stimulate hematopoietic stem cell generation in healthy bone marrow donors...
- Enhancing neutrophil function in neutropenia-related pneumoniaHongbo R Luo; Fiscal Year: 2012..b>Neutropenia and related infection are the most important dose limiting toxicities of these anti-cancer treatments, ..
- Genetics and visualization of innate host response to C. albicans infection in viRobert T Wheeler; Fiscal Year: 2012..bloodstream candidemia carries a >30% attributable mortality and is associated with chemotherapy-induced neutropenia, organ transplantation, primary genetic defects such as chronic granulomatous disease, and medical procedures ..
- Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in UgandaSunil Parikh; Fiscal Year: 2013..pregnant women, and are associated with significant drug interactions and heightened toxicities, in particular neutropenia, in the setting of HIV infection and concomitant ART...
- Long-acting growth factors for treating the acute and long term effects of lethalChristie M Orschell; Fiscal Year: 2013..These proteins are used to treat chemotherapy-related neutropenia and thrombocytopenia in cancer patients...
- A Mouse model of Barth syndrome, a mitochondrial cardiolipin disorderZaza Khuchua; Fiscal Year: 2013..and characterized by dilated cardiomyopathy, skeletal myopathy, chronic fatigue, exercise intolerance, cyclic neutropenia and organic aciduria...
- Instant Pediatric POC Blood AnalysisNEVEN KARLOVAC; Fiscal Year: 2012..The analyzer would be used for monitoring of anemia in children;neutropenia in children;evaluation for infections (total white count, increased white blood cells with neutrophil ..
- Mechanisms of G-CSF-Induced NeuroprotectionJiping Tang; Fiscal Year: 2012..It has been widely used in clinical practice for the treatment of neutropenia associated with cytotoxic therapy...
- Molecular Mechanisms of MyelokathexisAndrew Aprikyan; Fiscal Year: 2009..Abstract Myelokathexis is a rare congenital autosomal dominant disorder characterized by severe chronic neutropenia or leukopenia...
- Parathyroid Hormone in Prevention and Mitigation of ThrombocytopeniaAMELIA M BARTHOLOMEW; Fiscal Year: 2010..radiation injury to the bone marrow will lead to anemia, thrombocytopenia, and infectious complications due to neutropenia. Part of an effective treatment regimen for this syndrome includes blood transfusions, however it is estimated ..
- Molecular Mechanism of Severe Congenital NeutropeniaH Grimes; Fiscal Year: 2009DESCRIPTION (provided by applicant): Severe Congenital Neutropenia (SCN) predisposes affected humans to opportunistic infections because of a profound deficiency in the production of neutrophils...
- Endothelial Progenitor Cell Transplant to Accelerate Hematopoietic RecoveryJohn P Chute; Fiscal Year: 2011..blood transplantation (CBT) in adults, delayed donor cell engraftment can result in profound and persistent neutropenia, thrombocytopenia and immune suppression leading to increased mortality risk...
- Synthetic glycopeptide vaccines that enhance resistance to candidiasisHong Xin; Fiscal Year: 2013..b>Neutropenia is one of the most common risk factor for the development of hematogenously disseminated candidiasis in humans...
- HEPylated G-CSF: Drug with Safer, Enhanced Delivery for Neutropenia TreatmentWei Jing; Fiscal Year: 2011..a current drug, a long acting version of granulocyte colony stimulating factor (G-CSF) used in the treatment of neutropenia (abnormally low white blood cell counts). PEGylated G-CSF, Neulasta ($4...
- Novel indication for myeloid progenitor use: Induction of toleranceTimothy C Fong; Fiscal Year: 2013..White blood cell counts fall precipitously, resulting in neutropenia and increased susceptibility to infections To reduce infections associated with neutropenia in HCT recipients, ..
- ELANE and CSF3R mutations in severe congenital neutropeniaFan Dong; Fiscal Year: 2012DESCRIPTION (provided by applicant): Severe congenital neutropenia (SCN) is a group of heterogeneous disorders characterized by severe absolute neutropenia and a maturation arrest of myeloid cells at the promyelocyte stage...
- Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccineDon J Diamond; Fiscal Year: 2013..to limit progression from viremia to disease but also have significant side effects, including exacerbating neutropenia, delay of immune reconstitution, and renal toxicity in the case of FOS...
- Oral Agents to Stimulate Neutrophil ProductionSUSAN PARK PERRINE; Fiscal Year: 2010..SCFADs can stimulate myelopoiesis (the production of neutrophils) in vitro and in vivo in an animal model of neutropenia. Preclinical development of a lead Hemokine, ST7, was begun for a non- myelopoietic indication...
- Iron Uptake and Mucormycosis PathogenesisAshraf S Ibrahim; Fiscal Year: 2013..is a life-threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis (DKA), neutropenia, corticosteroid use, and/or increased serum iron...
- Dynamics of neutrophil trafficking in Granulocytic AnaplasmosisJENNIFER LYNN JOHNS; Fiscal Year: 2011..In contrast to endotoxin-positive bacterial infections, A. phagocytophilum infection induces neutropenia despite increased bone marrow (BM) granulopoiesis...
- Dynamics of neutrophil trafficking in Granulocytic AnaplasmosisJENNIFER LYNN JOHNS; Fiscal Year: 2013..In contrast to endotoxin-positive bacterial infections, A. phagocytophilum infection induces neutropenia despite increased bone marrow (BM) granulopoiesis...
- Third Bone Marrow Failure Disease Scientific SymposiumRichard M Stone; Fiscal Year: 2012..to produce blood cells, the resulting anemia, thrombocytopenia (shortage of platelets in the bloodstream), and neutropenia (neutrophil shortage) can lead to debilitating symptoms and death...
- Organ-specific Ugt1 profiling in detoxifying the anticancer drug CPT-11Shujuan Chen; Fiscal Year: 2013..However, its efficacy and safety is compromised because of severe neutropenia and late diarrhea, the side-effects resulting from CPT-11 bioactivation and subsequent metabolism...
- CLONAL DOMINANCE OF HEMATOPOIETIC STEM CELLS EXPRESSING MUTANT CSF3RDaniel C Link; Fiscal Year: 2013..Severe congenital neutropenia (SCN) is a bone marrow failure syndrome characterized by a marked propensity to develop acute myeloid leukemia...
- The Influence of Hospital Variability on the Management of Cancer-Associated CompJason Wright; Fiscal Year: 2013..will determine the quality of treatment for hospitalized patients admitted with a primary diagnosis of: febrile neutropenia, hypercalcemia of malignancy, esophagitis, and acute cancer-associated pain...
- Biosynthesis and Function of Lactosaminyl Glycans in HematopoiesisRobert Sackstein; Fiscal Year: 2013DESCRIPTION (provided by applicant): Infection and bleeding secondary to neutropenia and thrombocytopenia, respectively, are the major causes of near-term morbidity and mortality from chemoradiotherapy...
- Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)Charlotte Cunningham-Rundles; Fiscal Year: 2013..including the Center for International Blood and Marrow Transplantation Research (CIBMTR), the Severe Chronic Neutropenia International Registries (SCNIR) and the Clinical and Translational Science Award (CTSA) sites that pursue ..
- Microfluidic neutrophil counter for at-home use by chemotherapy patientsYu Hwa Lo; Fiscal Year: 2013..b>Neutropenia, characterized by an abnormally low number of neutrophils that serve as the primary defense against infections, ..
- Molecular basis of neutrophil spontaneous deathHongbo R Luo; Fiscal Year: 2010..Accelerated neutrophil death leads to a decrease of neutrophil counts (neutropenia), while delayed neutrophil death elevates neutrophil counts (neutrophilia)...
- eCancer: A technological approach to symptom management from home to practiceBRIAN DAVID DECKER; Fiscal Year: 2010..Despite pretreatment supportive care regimens for anemia, neutropenia, nausea and vomiting, levels of burden for such symptoms as pain, fatigue, shortness of breath and loss of ..
- Understanding cell migration through microscale in vitro modelsAnna Huttenlocher; Fiscal Year: 2013..system - specifically the role of Hax1 signaling in neutrophil chemotaxis in the context of severe congential neutropenia (SCN)...
- MicroRNA in Acute Myeloid LeukemiaH Leighton Grimes; Fiscal Year: 2013..granulopoiesis, inhibits myeloid progenitor proliferation, and is mutated in patients with severe congenital neutropenia (SCN). SCN patients are at increased risk for AML...
- Structural requirements for immunostimulation by plant lipidsAkira Kawamura; Fiscal Year: 2013..Although chemotherapy-induced neutropenia can be alleviated with recombinant granulocyte colony-stimulating factor, therapeutic options to treat damages ..
- Severe Chronic Neutropenia International RegistryDAVID CHANDLER DALE; Fiscal Year: 2013The Severe Chronic Neutropenia International Registry (the Registry) opened in 1994 to study the long-term safety and efficacy of granulocyte-colony stimulating factor (G-CSF) treatment for patients with congenital, cyclic and ..
- Transfusion Medicine/Hemostasis Clinical Research NetworkRonald G Strauss; Fiscal Year: 2012..Many millions more have problems with thrombocytopenia, neutropenia and anemia...
- CONTROL OF HEMATOPOIETIC TOXICITY WITH INTERLEUKIN-1VINCENT GALLICCHIO; Fiscal Year: 1990..Specifically, this toxicity results in the development of neutropenia and/or thrombocytopenia...
- DEVELOPMENT OF A CD-ROM OF CHROMATOGRAPHIC IMAGESDavid Becker; Fiscal Year: 1993..in patients with colonic cancers or cancers which have metastasized to the colon, leukemia and cyclic neutropenia. Mortality from C...
- Mechanism for copper-deficiency mediated neutropeniaDennis J Thiele; Fiscal Year: 2013..Cu deficiency causes severe neutropenia, a depletion of the phagocytic cells that represent the first line of defense in bacterial and fungal ..
- TMH Clinical Trials Network-Wisconsin Core Clinical CenterJANICE G MC FARLAND; Fiscal Year: 2012..A Randomized Clinical Trial" (STAR) and "High Dose Granulocyte Transfusions for the Treatment of Infections in Neutropenia" (the Granulocyte Trial)) and others as they are developed and approved...
- Notch-Mediated Expansion of Cord Blood Progenitors for Stem Cell TransplantColleen Delaney; Fiscal Year: 2013..is associated with increased risk of early transplant related mortality due to a prolonged period of severe neutropenia post transplant...
- Human Cathepsin G: Expression, C-Terminal Processing and Dual SpecificityDavid Johnson; Fiscal Year: 2007..In the case of HNE, failure to remove this peptide results in trafficking to the membrane and neutropenia. In Aim#1 these proteases will be expressed as active recombinant enzymes via secretion from the methanolic ..
- REACTIONS TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN AIDSManuel Lopez; Fiscal Year: 1990..sulfamethoxazole- trimethoprim, which are highly suggestive of hypersensitivity; symptoms include worsening of neutropenia and thrombocytopenia, diffuse skin rash, persistent fever, and occasionally shock...
- Hematopoietic Stem Cells & Lympho-Hematopoiesis: Effect of AlcoholROBERT WOLCOTT; Fiscal Year: 2007..The deleterious effects of chronic alcohol include thrombocytopenia, neutropenia and lymphopenia, as well as pancytopenia...
- Restoring Hematopoiesis Following Radiation InjuryAmelia Bartholomew; Fiscal Year: 2005..which the attendant morbidities of anemia, thrombbcytopenia, and the infectious complications associated with neutropenia, can be treated with both colony-stimulating factors, aggressive use of anti-microbials, and stem cell ..
- Molecular Studies of Severe Congenital NeutropeniaAndrew Aprikyan; Fiscal Year: 2005DESCRIPTION: (provided by applicant) Severe congenital neutropenia (SCN) is characterized by a selective decrease in the number of circulating1 neutrophils associated with recurrent fevers, chronic oropharyngeal inflammation and ..
- HOME CARE FOR FEVER AND NEUTROPENIA--A RANDOMIZED TRIALJames Talcott; Fiscal Year: 1999..of two alternative treatment settings for the antibiotic therapy of low-risk cancer patients with fever and neutropenia. Early discharge to home antibiotic therapy will be compared to the usual pattern of care, which is to keep ..
- MARROW SUPPRESSION FROM A LENTIVIRUSJANIS ABKOWITZ; Fiscal Year: 1993..Cats infected with FTLV develop recurrent infections, diarrhea, neurological abnormalities, lymphopenia, neutropenia and anemia. We will study the interaction of FTLV and hematopoietic progenitors in vitro and in vivo...
- P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLYELIZABETH DEES; Fiscal Year: 2006..In the second clinical trial, age-related decline in CYP3A4 activity and its impact on clearance and neutropenia in patients treated with vinorelbine will be evaluated...
- Iron Uptake and Mucormycosis PathogenesisAshraf Ibrahim; Fiscal Year: 2005..is a life-threatening infection that occurs in patients who are immunocompromised due to diabetic ketoacidosis, neutropenia, organ transplantation, and/or increased available serum iron...
- Monoclonal antibodies to inhibit Aspergillus germinationMARTA L FELDMESSER; Fiscal Year: 2010..pathogen, causes invasive disease in severely immunocompromised patients, most often in those with profound neutropenia or who have undergone organ transplantation...
- Radioimmunotherapy for LymphomaThomas Witzig; Fiscal Year: 2002..The primary toxicity of Y2B8 is reversible myelosuppression, which results in neutropenia and thrombocytopenia and the concomitant increased risk for infection or bleeding...
- Scientific and Medical Meetings about Barth syndromeMatthew J Toth; Fiscal Year: 2010..Cardiomyopathy and neutropenia are the main causes of morbidity and mortality in Barth syndrome, and clinical advancements in these particular ..
- LIVER TRANSPLANT ASSOCIATED CYTOMEGALOVIRUS PREVENTIONDavid Snydman; Fiscal Year: 1991..01). The study also showed a significant reduction in neutropenia (p less than 0.01) and in fungal or parasitic complications (p equal to 0.02)...
- Targeted Therapy of Lyn in Myelodysplastic SyndromeSETH JOEL COREY; Fiscal Year: 2010..Receptor signaling is found in several forms of pediatric and adult MDS: 1) children with severe congenital neutropenia have a 10,000-fold increase risk of developing MDS/AML - almost all of whom express a truncated G-CSF Receptor;..
- HUMAN GRANULOCYTIC EHRLICHIOSIS: NORTH CENTRAL U.S.Russell Johnson; Fiscal Year: 2005..The HGE agent infects blood polymorphonuclear neutrophils resulting in neutropenia and a thrombocytopenia. HGE may be a mild to potentially fatal disease...
- G-CSF Receptor and UbiquitinationBelinda Avalos; Fiscal Year: 2006..regulating granulopoiesis and the current widespread clinical use of G-CSF for prevention and/or treatment of neutropenia and for stem cell mobilization, the molecular mechanisms that downregulate G-CSFR expression and signaling to ..
- CLINICAL AND CLASSICAL EPIDEMIOLOGY IN ONCOLOGYJames Talcott; Fiscal Year: 1991..The current study applies these techniques to cancer patient populations: those with fever and neutropenia and those with suspected spinal cord compression...
- BIOARTIFICIAL MUSCLES FOR GENE THERAPYHerman Vandenburgh; Fiscal Year: 2002Recombinant proteins are used to treat a number of human disorders including diabetes, neutropenia, anemia, and musculoskeletal disorders of the elderly...
- DYSREGULATION OF APOPTOSIS IN LGL LEUKEMIAThomas Loughran; Fiscal Year: 2000..LGL leukemia is a clonal lymphoproliferative disease associated with neutropenia and autoimmune features...
- ATTENUATION OF MUSCLE WASTING WITH GROWTH HORMONEHerman Vandenburgh; Fiscal Year: 2000Recombinant proteins are used to treat a number of human disorders including diabetes, neutropenia, anemia, and, more recently, chronic musculoskeletal disorders of the elderly...
- Immune Recovery Following LLME Treated Cell TherapyJoanne Filicko; Fiscal Year: 2006..Following resolution of neutropenia early after HSCT, infectious risk correlates with patients' CD4 counts, much as is the case in HIV ..